Know Cancer

forgot password

Prospective Observational Study of Patients With Locally Advanced Gastric Cancer Treated With Perioperative Chemotherapy and Surgery

19 Years
80 Years
Open (Enrolling)
Gastric Cancer

Thank you

Trial Information

Prospective Observational Study of Patients With Locally Advanced Gastric Cancer Treated With Perioperative Chemotherapy and Surgery

Chile belongs to the countries with a high mortality rate due to gastric cancer, and this
disease is the most frequent cause of cancer death in Chile. Despite of adequate surgery,
survival rates are disappointing, with less than 60% of patients for all stages achieving to
be alive at 5 years. This is due to the fact that frequently gastric cancer is diagnosed at
an advanced stage. For locally advanced gastric cancer a multimodality treatment is
recommended, with the alternatives of surgery followed by chemotherapy (asian approach),
surgery followed by chemoradiation (US approach) and perioperative chemotherapy (european
approach). These three strategies are valid standard treatment options and have shown to
improve overall survival in stage IB to IVA gastric cancer.

Perioperative chemotherapy administered pre- and postoperatively, has shown to downstage the
tumor, increase curative resection, progression free and overall survival.

For patients with potentially resectable gastric cancer staged T2 or higher or cN+, NCCN
Guidelines recommend perioperative chemotherapy (category1). Chilean guidelines for gastric
cancer state the alternative of perioperative chemotherapy, however this approach has not
been used widely in public hospitals because lack of financial support.

Some gastric cancers overexpress HER2, and this subset of patients benefit from targeted
therapy at an advanced stage. The proportions of patients with these molecular
characteristics vary widely depending of the geographic area. The chilean population has
been investigated in small series, but the incidence of HER2 positive gastric cancer is not
known. We therefore plan to measure HER2 expression in all participating patients.

Inclusion Criteria:

- Histologically proven invasive carcinoma

- Age > 18 years.

- ECOG performance status 0 or 1.

- Hemoglobin > 9 g/dL

- Absolute neutrophil count > 1.5 x 109/L

- Platelet count > 100 x 109/L

- Creatinine < 1.5 ULN

- Creatinine clearance > 60 mL/min

- Serum bilirubin < 1.5 x ULN

- AST < 2.5 x ULN

- Women of child bearing potential: must agree to use an effective contraceptive

- Signed informed consent.

Exclusion Criteria:

- ECOG > 2.

- Pre-existing diarrhea uncontrolled with supportive care.

- Inability to swallow Xeloda tablets.

- History of mild-to-moderate renal insufficiency (creatinine clearance < 45 mL/min).

- Signs or symptoms of clinically significant hepatic dysfunction (bilirubin > 1.5 ULN,
FA > 2.5 ULN, albumin < 2,5 g/dL).

- Significant cardiac dysfunction (LVEF < LLN)

- Presence of distant metastasis, including clinical signs of peritoneal carcinomatosis

- Symptomatic gastric retention or severe dysphagia with a caloric intake of < 1500

- Histology of lymphoma, GIST or neuroendocrine tumor

- Pregnant or breast-feeding women. Female patients must be postmenopausal, surgically
sterile or they must agree to use an effective method of contraception.

- Any medical conditions that, in the investigator's opinion, would impose excessive
risk to the patient. Examples of such conditions include congestive heart failure of
Class III or IV of the NYHA classification, infection requiring parental or oral
treatment, any altered mental status or any psychiatric condition that would
interfere with the understanding of the informed consent.

Type of Study:


Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

rate of downstaging

Outcome Description:

To determine the rate of downstaging of locally advanced cT3-4 and/or N+ gastric carcinomas after 3 cycles of preoperative chemotherapy with ECX

Outcome Time Frame:

3 months

Safety Issue:



Chile: Institutional Review Board

Study ID:

GOCCHI 2009-01



Start Date:

August 2010

Completion Date:

August 2015

Related Keywords:

  • Gastric Cancer
  • gastric cancer
  • combination chemotherapy
  • HER-2 gene
  • quality of life
  • Stomach Neoplasms